2024-10-18 09:39:00
Fina Lladós will chair Farmaindustria for the next two years. Lladós was already vice president of Farmaindustria and president of LAWG, the Association of American pharmaceutical companies operating in Spain.
<img width="1170" height="752" class="attachment-newpress-featured-large size-newpress-featured-large wp-post-image lazyload" alt="Fina Lladós, directora general de Amgen Iberia, nueva presidenta de Farmaindustria" decoding="async" fetchpriority="high" data-attachment-id="358976" data-permalink="https://efesalud.com/farmaindustria-nueva-presidenta-farmaceuticas/fina-llados/" data-orig-file="https://efesalud.com/wp-content/uploads/2024/10/Fina-Llados.jpeg" data-orig-size="1920,1280" data-comments-opened="0" data-image-meta="{"aperture":"3.5","credit":"LUIS CAMACHO","camera":"NIKON D750","caption":"","created_timestamp":"1729173789","copyright":"LUIS CAMACHO","focal_length":"165","iso":"1600","shutter_speed":"0.004","title":"","orientation":"1"}" data-image-title="Fina Llados" data-image-description="" data-image-caption="
Fina Lladós, general director of Amgen Iberia, new president of Farmaindustria. Photo provided.
” data-medium-file=” data-large-file=” tabindex=”0″ role=”button” src=” srcset=” 1170w, 370w” data-sizes=”auto” data-eio-rwidth=”1170 ” data-eio-rheight=”752″/>
Fina Lladós, general director of Amgen Iberia, new president of Farmaindustria. Photo provided.
The general director of the biotechnology company Amgen was unanimously elected president of the Extraordinary General Assembly of Farmaindustria this Thursday, succeeding Jesús Ponce, president of the Novartis Group, in office since October 2022.
The new president of the association has expressed her availability collaboration and listening explaining that it will establish links with all those who want health to be a good for society and an opportunity for the country.
Likewise, it has demonstrated its commitment to these goals: “I will work to generate trust and for the pharmaceutical industry to be trustworthy strategic for the economic and social development of Spain“, said the new president.
He also referred to the “unique moment” that the sector is experiencing, which both the Government and the European Commission, through the Draghi Report, position as a strategic sector for its exceptional contribution to research and development, to the balance of trade , economic development and quality job creation.
In this sense, Lladós invited us to “take advantage of this unprecedented opportunity with humility, trust and perseverance”.
A total of 12 vice presidents: Felipe Pastrana (Abbvie), Lidia Martín (Almirall), David Solanes (ERN), Sergi Aulinas (Gebro), Cristina Henríquez de Luna (Glaxosmithline), Manuel Zafra (Merck), Ana Argelich (Merck Sharp & Dohme), Jesús Ponce (Novartis), Carlos Murillo (Pfizer), Federico Plaza (Roche Farma), Juan López-Belmonte (Rovi) and Raquel Tapia (Sanofi-Aventis).
The succession takes place in accordance with the Statutes of FarmaindustriaWhich establishes an alternation of leadership of the organization between the groups of companies that make up the association according to the origin of its capital: national, European/international and American.
For the next two years the Presidency corresponds to the group of American capital companies.
<img decoding="async" width="1024" height="683" data-attachment-id="358977" data-permalink="https://efesalud.com/farmaindustria-nueva-presidenta-farmaceuticas/nueva-junta-directiva-de-farmaindustria/" data-orig-file="" data-orig-size="1920,1280" data-comments-opened="0" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="Nueva Junta Directiva de Farmaindustria" data-image-description="" data-image-caption="
New Board of Directors of Farmaindustria. Photo provided.
” data-medium-file=” data-large-file=” tabindex=”0″ role=”button” alt=”presidenta farmaindustria” class=”wp-image-358977 lazyload” src=” srcset=” 1024w, 300w , 768w, 1536w, 1200w, 1920w” data-sizes=”auto” data-eio-rwidth=”1024″ data-eio-rheight=”683″/>New Junta Directiva de Farmaindustria. Photo provided.
Profile of the new president of Farmaindustria
Fina Lladós graduated in Pharmacy from the University of Barcelona and subsequently completed a management development program at IESE, a postgraduate diploma in Industrial Medicine from the Autonomous University of Barcelona and a Master in Pharmaceutical Industry from the Center for Higher Studies of the Pharmaceutical Industry (Cesif).
With more than 25 years of experience in the pharmaceutical sectorHe began his career at Roche and Sanofi-Aventis and has worked at Amgen since 1999.
In this company he developed his career in the R&D area, as well as in the medical and commercial departments, both in Spain and at the company’s European headquarters in Switzerland.
Since 2017 he has been general director of Amgen Iberia.
#Fina #Lladós #president #Farmaindustria
